Siddhartha Kadia

Siddhartha C.
Kadia is President, Chief Executive Officer & Director at Mesa Laboratories, Inc. since 2026.
Holds director positions at ALS Ltd. (Independent Non-Executive Director since 2019), BioSkryb, Inc. (Director since 2020), Applied Technical Services LLC (Director since 2021), SeQure DX, Inc. (Director), and The Scripps Research Institute (Member-Overseers Board).
Formerly President, Chief Executive Officer & Director at Evans Analytical Group LLC; President, Chief Executive Officer & Director at Eurofins BioPharma Product Testing Columbia, Inc. from 2014 to 2018; President & Chief Executive Officer at Eurofins EAG Agroscience LLC from 2014 to 2018; Chief Executive Officer & Director at Bruker Cellular Analysis, Inc. from 2022 to 2023; Chief Executive Officer & Director at Phenomebio, Inc. from 2022 to 2023; Chief Executive Officer & Director at Calibre Scientific, Inc.; Independent Director at Newport Corp.
from 2014 to 2016; Independent Director at NuVasive LLC from 2021 to 2023; Independent Director at Philips Image Guided Therapy Corp.
from 2013 to 2015; Independent Director at IsoPlexis Corp.; Non-Executive Director at Horizon Discovery Group Ltd. in 2020; Independent Director at VIDA FLaSH Acquisitions; Director at Bioskryb Genomics, Inc.; Vice President-Global Marketing & eBusiness at Invitrogen Corp.
from 2005 to 2008; Neuroscientist at The Johns Hopkins University; President-Life Sciences Division at Life Technologies Corp.
from 2013 to 2014.
Education includes graduate degree from Rutgers State University of New Jersey, undergraduate degree from Gujarat University, and doctorate from The Johns Hopkins University School of Medicine.